Anti-Rat CD4 (Clone OX-38) – Purified in vivo PLATINUM™ Functional Grade

Anti-Rat CD4 (Clone OX-38) – Purified in vivo PLATINUM™ Functional Grade

Product No.: C753

- -
- -
Clone
OX-38
Target
CD4
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
T-cell surface glycoprotein CD4, T-cell surface antigen T4/Leu-3, W3/25 antigen
Isotype
Mouse IgG2a
Applications
Depletion
,
ELISA
,
FA
,
FC
,
IP

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Rat
Host Species
Mouse
Recommended Dilution Buffer
Immunogen
Lymphocytes or thymocyte glycoproteins
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
Depletion,
ELISA,
FA,
FC,
IP
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
OX-38 activity is directed against rat CD4.
Background
CD4 is a 55 kD single-chain type I transmembrane glycoprotein with four domains and is a member of the Ig superfamily1,2. CD4 functions primarily as a coreceptor for the MHC class II molecule-peptide complex and initiates the early phase of T-cell activation via its association with the T-cell receptor complex and protein tyrosine kinase Lck3. In addition, CD4 T lymphocytes are essential to the host response against infectious disease4 and CD4 T cells mediate neuronal damage in infectious and immune-mediated diseases of the central nervous system5. In macrophages and natural killer cells, CD4 plays a role in differentiation/activation, cytokine expression and cell migration3.

OX-38 was generated by immunizing mice with lymphocytes or thymocyte glycoproteins and subsequently fusing mouse spleen cells with the P3-X63/Ag 8 cell line6. OX-38 is a depleting monoclonal antibody used to study tolerance to allografts7,8,9,10,11 , Pneumocystis-host interaction4, and alopecia12 in rat models.

Antigen Distribution
CD4 is expressed on most thymocytes, a subset of T cells, and on monocytes/macrophages.
Ligand/Receptor
LCK, PTK2/FAK1, P4HB/PDI, IL16, MHCII alpha and beta chains
NCBI Gene Bank ID
UniProt.org
Research Area
Adaptive Immunity
.
Immunology
.
Autoimmunity

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone OX-38 is a monoclonal antibody that specifically targets the rat CD4 antigen. While it is not commonly used in mice due to its specificity for rat CD4, its applications in rats can inform potential analogous uses in mice with species-specific CD4 antibodies. In rats, OX-38 is used for:

  • In Vivo CD4+ T Cell Depletion: It has been used to deplete CD4+ T cells in vivo, which can be crucial for studying immune responses and tolerance.
  • Induction of Allograft Unresponsiveness: Injection of OX-38 mAb can induce unresponsiveness to allografts (transplants from genetically different individuals), though results vary by rat strain.
  • In Vitro Depletion of T Helper Cells: It has been used to deplete T helper cells from slice cultures in vitro.

If a similar antibody were used in mice, such as one targeting mouse CD4 (e.g., YTS 177 clone), it could be applied for analogous purposes like:

  • In Vivo CD4+ T Cell Depletion: Blocking or depleting CD4+ T cells to study immune responses.
  • Immune Response Modulation: Studying allograft tolerance or other immune responses in a mouse model.

However, specific applications for OX-38 in mice would not be directly relevant due to its rat-specificity.

Based on the available search results, there is limited specific information about antibodies commonly used alongside OX-38 in experimental studies. However, the search results do provide some relevant context about related antibodies and the CD4 research landscape.

Related CD4 Antibodies

The W3/25 antibody is closely related to OX-38, as both antibodies bind to the same epitope on the CD4 antigen. This suggests that W3/25 would be used in similar experimental contexts, though they would compete for binding rather than being used simultaneously. In contrast, the OX-35 antibody recognizes a different epitope on CD4 than OX-38, which could make it suitable for use in combination experiments or for targeting different functional aspects of the CD4 molecule.

Isotype Controls

For flow cytometry applications using OX-38, researchers commonly employ appropriate isotype controls. The Mouse IgG2a, κ isotype control is specifically recommended for use with OX-38, as it matches the antibody's isotype. This control is essential for determining background staining levels and ensuring accurate interpretation of flow cytometry data.

Functional Context

OX-38 is primarily used to identify and deplete CD4-expressing cells, including T helper cells, monocytes, and macrophages in rat models. Given its role in studying immune responses, it would likely be used alongside other T cell markers and immune cell antibodies, though the specific combinations are not detailed in the available literature.

The search results indicate that while OX-38 is well-characterized for its binding properties and applications, comprehensive information about commonly paired antibodies in published studies is not readily available in these sources.

Clone OX-38 is a mouse monoclonal antibody targeting rat CD4, cited extensively in immunological research primarily for its role in depleting or detecting CD4 T cells in rat models. The key findings from scientific literature that cite clone OX-38 are:

  • CD4 T Cell Depletion: OX-38 is widely used to selectively deplete CD4+ T cells in rats via administration of the antibody, facilitating the study of immune responses in the absence of helper T cells. This depletion strategy allows researchers to assess the specific contributions of CD4 T cells to disease models, vaccine efficacy, and immune regulation.

  • Epitope Specificity: OX-38 recognizes a distinct epitope on rat CD4 that differs from other commonly used anti-CD4 clones, such as W3/25 and OX-35. This specificity can be crucial for experimental design and interpreting results in flow cytometry or functional studies.

  • Application in Flow Cytometry: OX-38 is frequently employed in flow cytometry to identify, sort, or quantify rat CD4+ T cells. It is available in conjugated forms (such as PE-Cy7 or FITC) designed for multiparametric analysis of immune cell populations.

  • Comparison with Other Anti-CD4 Clones: OX-38 is often discussed alongside other monoclonal antibodies (e.g., W3/25, GK1.5, RM4-4, RM4-5), which differ in species reactivity and epitope recognition. Selection of OX-38 is recommended where its specificity for rat CD4 domain 1 is required.

  • Role in Immunological Experiments: OX-38 citations typically involve studies on rat immune function, autoimmunity, infection models, transplant biology, or vaccine studies, where manipulation or identification of CD4+ T cell populations is essential.

In summary, the antibody clone OX-38 is a key reagent for studying the function and dynamics of CD4+ T cells in rat models through depletion or detection, with its unique epitope specificity making it valuable for research requiring precise targeting of the CD4 molecule.

Dosing regimens for clone OX-38 (a rat anti-mouse CD4 monoclonal antibody) can vary across different mouse models based on factors such as the experimental aim (e.g., immune cell depletion vs. functional blocking), mouse strain, and disease context. However, detailed peer-reviewed dosing references specifically for OX-38 are limited in the provided results; the search produced more data on other monoclonal antibodies, such as anti-CD3, anti-PD-1, and OX-86 (anti-CD134).

Key context and supporting details:

  • Most in vivo antibody dosing guides recommend administering depleting or blocking monoclonal antibodies via intraperitoneal (i.p.) injection, typically at standard doses ranging from 100–500 μg per mouse for other rat anti-mouse antibodies, with schedules of every 3–7 days depending on the study design and biological endpoint.
  • Dosing regimens may be modified based on mouse strain. For example, nude mice (which lack T cells) often require adjusted timing or frequency due to altered tumor growth kinetics or differential immune responses compared to immunocompetent strains.
  • For antibodies of similar isotype and function to OX-38 (e.g., OX-86, an anti-CD134 rat IgG1), a typical regimen is 0.25 mg (250 μg) intraperitoneally, once daily for 3–7 consecutive days.
  • Fixed dosing (a set amount per mouse) is often preferred to mg/kg dosing for monoclonal antibodies in oncology, as antibody pharmacokinetics are less dependent on body weight and fixed dosing reduces variability between animals.

Points to consider for OX-38 in different mouse models:

  • Strain and immunocompetence: Sensitive strains or immunodeficient mice may require lower or less frequent doses to avoid toxicity or off-target effects.
  • Experimental endpoint: Depletion studies (such as CD4+ T cell removal) may require repeated or higher doses compared to transient blocking studies.
  • Route of administration: Intraperitoneal is standard, but intravenous and subcutaneous routes are sometimes used, typically with comparable dosing.
  • Literature-specific regimens: Although direct dosing data on OX-38 was not found in this search, published studies with closely related antibodies and standard dosing guides are typically referenced to set initial dosing parameters, which are then optimized per model and experiment.

If you require dosing for a specific disease model or experimental goal, searching for peer-reviewed literature referencing OX-38 in that precise context is advisable. When in doubt, start with established dosing (e.g., 200–500 μg i.p. every 3–7 days) and monitor for efficacy and toxicity, adjusting based on observed effects and study needs.

Summary table for context:

CloneTargetTypical DoseFrequencyRouteNotes
OX-38CD4200–500 μg/mouse*Every 3–7 days*IntraperitonealEstimate; confirm with primary literature
OX-86CD134250 μg/mouseDaily, 3–7 daysIntraperitonealUsed as reference for rat IgG1 antibodies
RMP1-14PD-1200 μg/mouseEvery 3–4 daysIntraperitonealExample from immunotherapy studies

*Estimated for OX-38 based on similar antibodies; confirm in pilot studies or relevant literature.

If you need precise, model-specific OX-38 regimens, direct primary references will yield the most reliable dosing information.

References & Citations

1. Lynch GW, Turville S, Carter B, et al. Immunol Cell Biol. 84(2):154-165. 2006.
2. Wittlich M, Thiagarajan P, Koenig BW, et al. Biochim Biophys Acta. 1798(2):122-127. 2010.
3. https://www.uniprot.org/uniprotkb/P05540/entry
4. Thullen TD, Ashbaugh AD, Daly KR, et al. Infect Immun. 71(11):6292-6297. 2003.
5. Brunn A, Utermöhlen O, Carstov M, et al. Am J Pathol. 173(1):93-105. 2008.
6. Jefferies WA, Green JR, Williams AF. J Exp Med. 162(1):117-127. 1985.
7. Flavin T, Shizuru J, Seydel K, et al. J Heart Transplant. 9(5):482-488. 1990.
8. Arima T, Lehmann M, Flye MW. Transplantation. 63(2):284-292. 1997.
9. Motoyama K, Arima T, Lehmann M, et al. Surgery. 122(2):213-219. 1997.
10. Qi Z, Riesbeck K, Ostraat O, et al. Transpl Immunol. 5(3):204-211. 1997.
11. Shizuru JA, Seydel KB, Flavin TF, et al. Transplantation. 50(3):366-373. 1990.
12. McElwee KJ, Spiers EM, Oliver RF. Br J Dermatol. 140(3):432-437. 1999.
Depletion
Indirect Elisa Protocol
FA
Flow Cytometry
Immunoprecipitation Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.